Advances in Therapy

, 26:40 | Cite as

Mecasermin (recombinant human insulin-like growth factor I)

Review
First Online:
Received:

Abstract

Growth hormone (GH) exercises its growth effects by stimulating insulin-like growth factor I (IGF-I) synthesis in the liver (endocrine IGF-I) and by inducing chondrocyte differentiation/replication and local production of IGF-I (paracrine/autocrine IGF-I). Injectable recombinant human (rh)IGF-I (mecasermin) has been available for nearly 20 years for treatment of the rare instances of GH insensitivity caused by GH receptor defects or GH-inhibiting antibodies. Full restoration of normal growth, as occurs with rhGH replacement of GH deficiency, is not seen, presumably because only the endocrine deficiency is addressed. RhIGF-I has also been effective as an insulin-sensitizing agent in severe insulin-resistant conditions. Although the insulin-sensitizing effect may benefit both type 1 and type 2 diabetes, there are no ongoing clinical trials because of concern about risk of retinopathy and other complications. Promotion of rhIGF-I for treatment of idiopathic short stature has been intensive, with neither data nor rationale suggesting that there might be a better response than has been documented with rhGH. Other applications that have either been considered or are undergoing clinical trial are based on the ubiquitous tissue-building properties of IGF-I and include chronic liver disease, cystic fibrosis, wound healing, AIDS muscle wasting, burns, osteoporosis, Crohn’s disease, anorexia nervosa, Werner syndrome, X-linked severe combined immunodeficiency, Alzheimer’s disease, muscular dystrophy, amyotrophic lateral sclerosis, hearing loss prevention, spinal cord injury, cardiovascular protection, and prevention of retinopathy of prematurity. The most frequent side effect is hypoglycemia, which is readily controlled by administration with meals. Other common adverse effects involve hyperplasia of lymphoid tissue, which may require tonsillectomy/adenoidectomy, accumulation of body fat, and coarsening of facies. The anti-apoptotic properties of IGF-I are implicated in cancer pathogenesis—a concern for long-term therapy. It is unlikely that mecasermin will be useful beyond the orphan indications of severe insulin resistance and GH insensitivity.

Keywords

cancer risk cardiovascular risk diabetes mellitus growth growth hormone insensitivity insulin resistance neurodegenerative disease osteoporosis recombinant insulin-like growth factor I retinopathy of prematurity 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Rosenbloom AL. The physiology of growth. Ann Nestlé. 2007;65:97–108.Google Scholar
  2. 2.
    de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306–312.PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell GS. Growth-hormone signal transduction. J Pediatr. 1997;131(suppl.):S42–S44.PubMedCrossRefGoogle Scholar
  4. 4.
    Rinderknech E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253:2769–2772.Google Scholar
  5. 5.
    Rinderknech E, Humbel RE. Primary structure of human insulin like growth factor II. FEBS Lett. 1978;89:283–287.CrossRefGoogle Scholar
  6. 6.
    Baxter RG, Binoux MA, Clemmons DR, et al. Recommendations for nomenclature of the insulin-like growth factor binding proteins superfamily. J Clin Endocrinol Metab. 1998;83:3213.PubMedCrossRefGoogle Scholar
  7. 7.
    Domené HM, Bengolea SV, Jasper HG, Boisclair YR. Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest. 2005;28(5 suppl.):43–46.PubMedGoogle Scholar
  8. 8.
    Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 2000;12:121–136.PubMedCrossRefGoogle Scholar
  9. 9.
    Woods KA, Camacho-Hübner C, Savage MO, Clark AJL. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335:1363–1367.PubMedCrossRefGoogle Scholar
  10. 10.
    Walenkamp MJ, Karperien M, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab. 2005;90:2855–2284.PubMedCrossRefGoogle Scholar
  11. 11.
    Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349:2211–2222.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawashima Y, Kanzaki S, Yang F, et al. Mutation at cleavage site of insulin like growth factor receptor in a short stature child born with intrauterine growth retardation. J Clin Endocrinol Metab. 2005;90:4679–4687.PubMedCrossRefGoogle Scholar
  13. 13.
    Walenkamp MJE, van der Kamp HJ, Pereira AM, et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin like growth factor I receptor. J Clin Endocrinol Metab. 2006;91:3062–3070.PubMedCrossRefGoogle Scholar
  14. 14.
    Inagaki K, Tiulpakov A, Rubtsov P, et al. A familial insulin like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab. 2007;92:1542–1548.PubMedCrossRefGoogle Scholar
  15. 15.
    Walenkamp MJE, de Muinck Keizer-Schrama SMPF, de Mos M, et al. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin like growth factor-I receptor due to a terminal 15q26.2->qter deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab. 2008;93:2421–2425.PubMedCrossRefGoogle Scholar
  16. 16.
    Hwa V, Camacho-Hübner C, Little BM, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68:218–224.PubMedCrossRefGoogle Scholar
  17. 17.
    Giudice LC, de Zegher F, Gargosky SE, et al. Insulin like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab. 1995;80:1548–1555.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growth in GH insensitivity. Trends Endocrinol Metab. 1994;5:296–303.PubMedCrossRefGoogle Scholar
  19. 19.
    Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987;6:426–438.Google Scholar
  20. 20.
    Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev. 1989;10:68–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor (GHR): effects on growth, growth mediators and body composition. Presented at: Pediatric Academic Societies Meeting; May 3, 2008; Honolulu, Hawaii.Google Scholar
  22. 22.
    McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007;157:S51–S56.PubMedCrossRefGoogle Scholar
  23. 23.
    Kemp SE, Thrailkill KM. SomatoKine: is there a use in treating growth disorders? Curr Opin Investig Drugs. 2005;6:373–377.PubMedGoogle Scholar
  24. 24.
    Guler HP, Zapf J, Froesch ER. Short-term metabolic effects and half-lives of intravenously administered insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317:137–140.PubMedGoogle Scholar
  25. 25.
    Rosenbloom AL, Ongley JP. Serum calcium phosphorus and magnesium decrement during oral glucose tolerance testing: alteration in pre-clinical and overt diabetes mellitus in childhood. In: Catin M, Selig M, eds. Magnesium in Health and Disease. Jamaica, NY: Spectrum Publishers Inc.; 1980: 297–304.Google Scholar
  26. 26.
    Guler H-P, Schmid C, Zapp J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989;86:2868–2872.PubMedCrossRefGoogle Scholar
  27. 27.
    Vaccarello MA, Diamond FBJr., Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab. 1993;77:273–280.PubMedCrossRefGoogle Scholar
  28. 28.
    Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, eds. The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa, NJ: Humana Press; 1999:739–769.Google Scholar
  29. 29.
    Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone 0. J Clin Endocrinol Metab. 1995;80:1393–1398.PubMedCrossRefGoogle Scholar
  30. 30.
    Crosnier H, Gourmelen M, Prëvot C, Rappaport R. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. J Clin Endocrinol. 1993;6:248–250.CrossRefGoogle Scholar
  31. 31.
    Wilson KF, Fielder PJ, Guevara-Aguirre J, et al. Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol. 1995;42:399–407.CrossRefGoogle Scholar
  32. 32.
    Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab. 1997;82:629–633.PubMedCrossRefGoogle Scholar
  33. 33.
    Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Ped Endocrinol Metab. 1995;8:149–158.Google Scholar
  34. 34.
    Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51:128–134.PubMedCrossRefGoogle Scholar
  35. 35.
    Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrin Metab. 2007;92:902–910.CrossRefGoogle Scholar
  36. 36.
    Camacho-Hubner C, Underwood LE, Yordam N, et al. Once daily rhIGF-I/rhIGFBP3 treatment improves growth velocity in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. Presented at: 88th Annual Meeting of The Endocrine Society; June 24–27, 2006; Boston, MA, 2006. Abstract OR 40-1.Google Scholar
  37. 37.
    Sjögren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96:7088–7092.PubMedCrossRefGoogle Scholar
  38. 38.
    Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor-I. Proc Natl Acad Sci U S A. 1999;96:7324–7329.PubMedCrossRefGoogle Scholar
  39. 39.
    Hwa V, Haeusler G, Pratt KL, et al. Total absence of functional acid labile subunit, resulting in severe insulin like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab. 2006;91:1826–1831.PubMedCrossRefGoogle Scholar
  40. 40.
    Domené HM, Bengolea SV, Martínez AS, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med. 2004;92:570–577.CrossRefGoogle Scholar
  41. 41.
    Domené HM, Scaglia P, Lteif A, et al. Phenotypic effects of null and haploinsufficiency of acid labile subunit in a family with two novel IGFALS gene mutations. J Endocrinol Metab. 2007;92:4444–4450.CrossRefGoogle Scholar
  42. 42.
    Camacho-Hübner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 2006;91:1246–1253.PubMedCrossRefGoogle Scholar
  43. 43.
    Clark RG. Recombinant insulin like growth factor-I as a therapy for IGF-I deficiency in renal failure. Pediatr Nephrol. 2005;20:290–294.PubMedCrossRefGoogle Scholar
  44. 44.
    Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I (rhIGF-I) in the treatment of idiopathic short stature? Lancet. 2006;368:612–616.PubMedCrossRefGoogle Scholar
  45. 45.
    Long-term treatment with rhIGF-I in GHIS. Available at: www.clinicaltrials.gov/ct2/show/NCT00571727?term=tercica&rank=10. Accessed December 20, 2008.Google Scholar
  46. 46.
    Treatment of children and adolescents with growth failure associated with primary insulin like growth factor I (IGF-I) deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00330668?term=tercica&rank=2. Accessed December 20, 2008.Google Scholar
  47. 47.
    Prepubertal children with growth failure associated with primary insulin like growth factor I (IGFI) deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00572156?term=tercica&rank=3. Accessed December 20, 2008.Google Scholar
  48. 48.
    Recombinant human insulin like growth factor (rhIGF-I) treatment of short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00125190?term=tercica&rank=7. Accessed December 20, 2008.Google Scholar
  49. 49.
    rhGH and rhIGF-I combination therapy in children with short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00572156?term=tercica&rank=4. Accessed December 20, 2008.Google Scholar
  50. 50.
    Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG. Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology. 1996;137:1913–1920.PubMedCrossRefGoogle Scholar
  51. 51.
    Rosenbloom AL. Hot topic. IGF-I treatment of diabetes. Pediatr Diabetes. 2001;2:123–130.PubMedCrossRefGoogle Scholar
  52. 52.
    Genentech discontinues IGF-I drug development effort in diabetes [press release]. San Francisco, CA: Genentech, Inc.; September 5, 1997. Available at: www.gene.com/gene/news/press-releases/display.do?method=detail&id=4842. Accessed December 20, 2008.Google Scholar
  53. 53.
    Cusi K, DeFronzo R. Recombinant human insulin like growth factor I treatment for one week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab. 2000;85:3077–3084.PubMedCrossRefGoogle Scholar
  54. 54.
    Study of recombinant human insulin like growth factor I in patients with severe insulin resistance. Available at: www.clinicaltrials.gov/ct2/show/NCT00004419?term=IGF-I&rank=44. Accessed December 20, 2008.Google Scholar
  55. 55.
    Insulin like growth factor I (IGF-I) and amyotrophic lateral sclerosis (ALS) trial. Available at: www.clinicaltrials.gov/ct2/show/NCT00035815?term=IGFI&rank=2. Accessed December 20, 2008.Google Scholar
  56. 56.
    A 48-week (24 week baseline followed by a 24 week treatment) phase II pilot study of the tolerability and effect/efficacy of subcutaneously administered insulin like growth factor -1 (rhIGF) (CEP-151) in multiple sclerosis (MS) Patients. Available at: www.clinicaltrials.gov/ct2/show/NCT00001669?term=IGF-I&rank=66. Accessed December 20, 2008.Google Scholar
  57. 57.
    Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in myotonic dystrophy type 1 (iPLEX). Available at: www.clinicaltrials.gov/ct2/show/NCT00233519?term=insmed&rank=2. Accessed December 20, 2008.Google Scholar
  58. 58.
    Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–1775.PubMedCrossRefGoogle Scholar
  59. 59.
    Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT. The role of IGF-I and its binding proteins in the development of type II diabetes and cardiovascular disease. Diab Obes Metab. 2008;10:198–211.CrossRefGoogle Scholar
  60. 60.
    Marleau S, Mulumba M, Lamontagne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res. 2006;69:26–35.PubMedCrossRefGoogle Scholar
  61. 61.
    Differential effects of rhGH versus rhIGF-I on cardiovascular risk factors. Available at: www.clinicaltrials.gov/ct2/show/NCT00684957?term=tercica&rank=9. Accessed December 20, 2008.Google Scholar
  62. 62.
    Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab. 2002;87:1593–1599.PubMedCrossRefGoogle Scholar
  63. 63.
    Descriptive study of recombinant human insulin like growth factor for osteoporosis in Werner syndrome. Available at: www.clinicaltrials.gov/ct2/show/NCT00004815?term=IGF-I&rank=189. Accessed December 20, 2008.Google Scholar
  64. 64.
    Effects of rhIGF-I on bone metabolism in adolescent girls with anorexia nervosa. Available at: www.clinicaltrials.gov/ct2/show/NCT00720122?term=IGFI&rank=87. Accessed December 20, 2008.Google Scholar
  65. 65.
    Smith LEH. Can we restore aspects of the in utero environment in premature infants to prevent disease? Pediatrics. 2004;114:491.PubMedCrossRefGoogle Scholar
  66. 66.
    Hansen-Pupp I, Engström E, Niklasson A, et al. Fresh-frozen plasma as a source of exogenous insulin like growth factor i in the extremely preterm infant. J Clin Endocrinol Metab. 2008; Nov 11 [Epub ahead of print].Google Scholar
  67. 67.
    Effect of Increlex™ on children with Crohn disease. Available at: www.clinicaltrials.gov/ct2/show/NCT00764699?term=tercica&rank=12. Accessed December 20, 2008.Google Scholar
  68. 68.
    Treatment for growth failure in patients with X-linked severe combined immunodeficiency: phase 2 study of insulin-like growth factor-1. Available at: www.clinicaltrials.gov/ct2/show/NCT00490100?term=IGF-I&rank=4. Accessed December 20, 2008.Google Scholar
  69. 69.
    Evaluation the growth factors (IGF-1,IGFBP-3 and HGH) in patients with chronic liver disease. Available at: www.clinicaltrials.gov/ct2/show/NCT00679692?term=IGF-I&rank=20. Accessed December 20, 2008.Google Scholar
  70. 70.
    IGF-I therapy in patients with cystic fibrosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566241. Accessed January 25, 2009.
  71. 71.
    Assessment of mechanisms of improved wound healing. Available at: http://clinicaltrials.gov/ct2/show/NCT00673309?term=mechanisms+of+improved+wound+healing&rank=1. Accessed January 25, 2009.
  72. 72.
    Dudgeon WD, Phillips KD, Carson JA, et al. Counteracting muscle wasting in HIV-infected individuals. HIV Med. 2006;7:299–310.PubMedCrossRefGoogle Scholar
  73. 73.
    Hollis ERII, Lu P, Blesch A, Yuszynski MH. IGF-I gene delivery promotes cortical spinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol. 2009;215:53–59.PubMedCrossRefGoogle Scholar
  74. 74.
    Carro E, Trejo JL, Gerber A, et al. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging. 2005;27:1250–1257.PubMedCrossRefGoogle Scholar
  75. 75.
    Iwai K, Nakagawa T, Endo T, et al. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope. 2006;116:529–533.PubMedCrossRefGoogle Scholar
  76. 76.
    Rosenbloom AL, Francke U, Rosenfeld RG, Guevara-Aguirre J. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab. 1999;84:4436–4443.PubMedCrossRefGoogle Scholar
  77. 77.
    Vasconez O, Martinez V, Martinez AL, et al. Heart rate increase in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr. 1994;399:137–139.CrossRefGoogle Scholar
  78. 78.
    Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndromic increases adiposity. Growth Horm IGF Res. 2006;16:61–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. J Pediatr Endocrinol Metab. 2008;21:381–384.PubMedGoogle Scholar
  80. 80.
    Samani AA, Yakar S, LeRoith D, Brodt P. The role of IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28:20–47.PubMedCrossRefGoogle Scholar
  81. 81.
    Perry JK, Emerald BS, Mertani HC, Lovie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277–289.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  1. 1.Adjunct Distinguished Service Professor Emeritus, Department of PediatricsUniversity of Florida College of Medicine, Children’s Medical Services CenterGainesvilleUSA

Personalised recommendations